Revue medicale de Liege最新文献

[Screening for sleep apnea-hypopnea syndrome : data from Liège University Hospital Center with a mandibular movement measurement device (Brizzy]. [筛选睡眠呼吸暂停-低通气综合征：数据来自li法兰西大学医院中心下颌运动测量装置（Brizzy）]。

Revue medicale de Liege Pub Date : 2025-09-01

Simon Peerboom, Celena Azouaoui, Valérie Quaedvlieg, Julien Fanielle, Olivier Bonhomme, Pierre Maquet, Renaud Louis

{"title":"[Screening for sleep apnea-hypopnea syndrome : data from Liège University Hospital Center with a mandibular movement measurement device (Brizzy].","authors":"Simon Peerboom, Celena Azouaoui, Valérie Quaedvlieg, Julien Fanielle, Olivier Bonhomme, Pierre Maquet, Renaud Louis","doi":"","DOIUrl":"","url":null,"abstract":"Obstructive sleep apnea-hypopnea syndrome (OSAHS) is an underrated and heavy public health problem. Polysomnography (PSG) remains GOLD-standard examination but we also use ambulatory screening tests including Brizzy, which measures mandibular movements. The aim is to report on our experience with the Brizzy and compare it with PSG data. Data from 812 patients clinically suspected of having OSAHS who underwent a Brizzy screening test prescribed at the University Hospital of Liège between 2012 and 2020 were collected and analyzed retrospectively. These data were compared with data from their subsequent PSG, when available. The characteristics of patients with a positive Brizzy test, i.e., a respiratory disturbance index (RDI) > 15 h-1, were those typically described, namely a majority of men over the age of 50 who were obese. Sixty-seven percent of the patients evaluated had an RDI > 15 h-1, and this index correlated with the apnea-hypopnea index (AHI) on PSG (R = 0.47, p < 0.0001). Only 26 % of patients with a positive Brizzy test underwent PSG within two years. A Brizzy IPR > 15 h-1 has a sensitivity of 97 % and a positive predictive value of 90 % for detecting an AHI > 15 h-1 on PSG. Thus, the IPR measured by mandibular movements using the Brizzy is an interesting tool for screening for OSAHS.","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 9","pages":"606-611"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Impact of the «ELADEB» tool and a case manager for hospitalized patients with complex care]. [«ELADEB»工具和病例管理器对复杂护理住院患者的影响]。

Revue medicale de Liege Pub Date : 2025-09-01

Gilles Henrard, Jean-Luc Belche, Isabelle Heymans, Nathalie Maes, Joy Josseaux, Éric Adam

{"title":"[Impact of the «ELADEB» tool and a case manager for hospitalized patients with complex care].","authors":"Gilles Henrard, Jean-Luc Belche, Isabelle Heymans, Nathalie Maes, Joy Josseaux, Éric Adam","doi":"","DOIUrl":"","url":null,"abstract":"Patients with complex care needs present numerous challenges: the care they receive is often associated with more hospital admissions. The care provided to this group could benefit from being more goal-oriented and better integrated. However, strengthening a net-work of care for these patients starting from hospitalization remains a challenge. This is particularly due to the fact that available assessment tools poorly reflect patient overall needs, especially psychosocial ones, and do not help identify their priorities.Therefore, we implemented a care strategy that includes the use of the ELADEB tool combined with the intervention of a case manager. We present the results of a retrospective study using administrative data from 109 hospitalized patients. We measured the effect of this intervention by comparing the number and duration of hospitalizations, as well as the number of readmissions within 30 days of discharge, one year before the intervention and one year after. We observed a statistically significant decrease in unplanned hospitalizations, average lengths of stay, and readmissions in the year following the intervention. These exploratory results highlight the potential value of such an intervention, yet a rigorous prospective evaluation in our context remains to be done.","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 9","pages":"584-591"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Plea for an early diagnosis of people at risk of developing symptomatic type 1 diabetes]. [呼吁对有患1型糖尿病症状风险的人进行早期诊断]。

Revue medicale de Liege Pub Date : 2025-09-01

André Scheen, Madeleine Wera, Jean-Christophe Philips, Julie Fudvoye, Marie-Christine Lebrethon, Nicolas Paquot

{"title":"[Plea for an early diagnosis of people at risk of developing symptomatic type 1 diabetes].","authors":"André Scheen, Madeleine Wera, Jean-Christophe Philips, Julie Fudvoye, Marie-Christine Lebrethon, Nicolas Paquot","doi":"","DOIUrl":"","url":null,"abstract":"Type 1 diabetes (T1D) is an autoimmune chronic disease that leads to the destruction of pancreatic beta cells and thus requires lifelong insulin therapy. Constraints and adverse events associated to insulin therapy are well known as well as the risk of long-term complications linked to chronic hyperglycaemia. Symptomatic T1D is preceded by a preclinical asymptomatic period, which is characterized by the presence of at least two auto-antibodies against beta cell without disturbances of blood glucose control (stage 1) or, in addition to immunological biomarkers, by the presence of mild dysglycaemia reflecting a defect of early insulin secretion (stage 2). Recent objectives for the management of this disease are to detect people with auto-antibodies in order to propose an early specific management to delay the shift to clinical stage (stage 3) and to limit its severity as well. The screening concerns as first step relatives of patients living with T1D and individuals presenting other auto-immune diseases, but may be extended to the general population (especially in young people) with the improvement of techniques of auto-antibody assays. Teplizumab, an anti-CD3 monoclonal antibody, slows down the decline of insulin secretion by beta cells, both in people at stage 2 and early stage 3. This medication, which may be considered as a disease-modifying agent of T1D, was approved in November 2022 by the U.S. Food and Drug Administration (FDA) and is currently evaluated by the European Medicines Agency (EMA).","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 9","pages":"598-605"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Traumatic pulmonary pseudocyst]. [创伤性肺假性囊肿]。

Revue medicale de Liege Pub Date : 2025-09-01

Arnaud Lempereur, Michèle Yerna, Ali Deeba

引用次数: 0

[Biomarkers for an early detection of patients at risk of renal or cardiovascular disease]. [早期发现有肾脏或心血管疾病风险的患者的生物标志物]。

Revue medicale de Liege Pub Date : 2025-09-01

André Scheen, Pierre Delanaye, François Jouret, Patrizio Lancellotti, Étienne Cavalier

引用次数: 0

[Focus on bariatric endoscopy in Belgium]. [关注比利时的肥胖内窥镜检查]。

Revue medicale de Liege Pub Date : 2025-09-01

Julien Barras, Édouard Louis, Jean-Philippe Loly

{"title":"[Focus on bariatric endoscopy in Belgium].","authors":"Julien Barras, Édouard Louis, Jean-Philippe Loly","doi":"","DOIUrl":"","url":null,"abstract":"Bariatric endoscopy is an increasingly recognized alternative to surgery for obesity treatment. Recent guidelines from leading medical societies (IFSO, ASMBS, ASGE, ESGE) have included endoscopic sleeve gastroplasty (ESG) and the intragastric balloon (IGB) in their recommendations. These procedures are indicated for patients with a body mass index (BMI) between 27 and 40 kg/m² who cannot or do not wish to undergo surgery. ESG reduces stomach volume through endoscopic suturing of the gastric wall, leading to early satiety and an average total weight loss of 16 % within 12 months. While less effective than surgical sleeve gastrectomy, it carries significantly fewer severe complications. The IGB, temporarily placed in the stomach, allows for moderate weight loss (10-15 % of total weight), but weight regain is almost inevitable after removal. However, it can be useful preoperatively or as an adjunct to other treatments. Other emerging endoscopic devices (EndoBarrier, duodenal resurfacing, etc.) show promise, but their safety and efficacy remain to be confirmed. The future of these techniques will depend on their long-term efficacy/risk recognition and reimbursement, particularly in Belgium, where they are not yet covered by health insurance.","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 9","pages":"576-583"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[One-year clinical results of the Multidisciplinary Consultation at the Emphysema Clinic of CHU Liege]. 【朱列日肺气肿门诊多学科会诊1年临床结果分析】。

Revue medicale de Liege Pub Date : 2025-09-01

Romain Alfieri, Bernard Duysinx, Renaud Louis, Vincent Heinen

{"title":"[One-year clinical results of the Multidisciplinary Consultation at the Emphysema Clinic of CHU Liege].","authors":"Romain Alfieri, Bernard Duysinx, Renaud Louis, Vincent Heinen","doi":"","DOIUrl":"","url":null,"abstract":"Severe emphysema impairs lung function and quality of life in patients with Chronic Obstructive Pulmonary Disease (COPD). Despite optimized medical treatment and rehabilitation, some patients require lung volume reduction interventions (endoscopic or surgical). This study evaluates one-year outcomes of patients managed at the Emphysema Clinic of CHU Liège. This retrospective observational and longitudinal single-center study included 65 patients discussed in multidisciplinary meetings between 2021 and 2023. Patients were divided into two groups: treated (n = 24) with bronchoscopic lung volume reduction (BLVR) using endobronchial valves (EBV), lung volume reduction surgery (LVRS), or referred for lung transplantation (LTx); and non-treated (n = 41). Clinical and functional parameters were compared at baseline (T0) and after one year (T1). At one year, treated patients showed a significant improvement in forced expiratory volume in 1 second (FEV1 : +8.19 %, p = 0.0051), six-minute walk test distance (+54.6 m, p = 0.018), and COPD Assesment Test (CAT score : -5.3 points, p = 0.0017). Advanced interventions for emphysema improve respiratory function, walking distance and quality of life in selected patients based on strict criteria and multidisciplinary consultation.","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 9","pages":"567-575"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Ileal diverticulitis, a rare etiology of digestive bleeding]. [回肠憩室炎，消化道出血的罕见病因]。

Revue medicale de Liege Pub Date : 2025-09-01

Sonia Mendil, Maud Van Buggenhout, Emmanuel Decker, Raphaelle Massa, Flavien Grandjean

引用次数: 0

[Tirzepatide (Mounjaro®) : a GIP/GLP-1 receptor dual agonist for the treatment of type 2 diabetes]. tizepatide （Mounjaro®）：用于治疗2型糖尿病的GIP/GLP-1受体双重激动剂。

Revue medicale de Liege Pub Date : 2025-09-01

André Scheen

{"title":"[Tirzepatide (Mounjaro®) : a GIP/GLP-1 receptor dual agonist for the treatment of type 2 diabetes].","authors":"André Scheen","doi":"","DOIUrl":"","url":null,"abstract":"Tirzepatide is a unimolecular dual agonist of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, recently commercialized and reimbursed in Belgium for the treatment of type 2 diabetes (T2D). Because of the complementarity of action of the two incretins, tirzepatide showed, in a dose-dependent manner (5, 10 and 15 mg as a once-weekly subcutaneous injection), a better efficacy (greater reduction in HbA1c and body weight) compared with placebo, semaglutide 1 mg, basal insulin and preprandial boluses of insulin lispro in six studies of the SURPASS programme. Tirzepatide tolerance is almost similar to that of pure GLP-1 receptor agonists, with digestive adverse events, most often during the first weeks after initiation, which justifies the recommendation of progressive titration every four weeks. Tirzepatide is now refunded under conditions in Belgium for the treatment of TD2 in patients with a body mass index ≥ 30 kg/m² and a HbA1c level > 7.5 % with antihyperglycaemic therapy including metformin. These reimbursement conditions are similar to those of pure GLP-1 receptor agonists but are more restrictive than the indications validated by the European Medicines Agency and the latest guidelines by international scientific societies.","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 9","pages":"618-624"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[How do I treat ANCA vasculitis with renal involvement]. 【如何治疗累及肾脏的ANCA血管炎】。

Revue medicale de Liege Pub Date : 2025-09-01

Maxime Crucil, Céline Regnier, Christian Von Frenckell, Stéphanie Grosch, François Jouret, Antoine Bouquegneau

{"title":"[How do I treat ANCA vasculitis with renal involvement].","authors":"Maxime Crucil, Céline Regnier, Christian Von Frenckell, Stéphanie Grosch, François Jouret, Antoine Bouquegneau","doi":"","DOIUrl":"","url":null,"abstract":"ANCA-associated vasculitis, such as granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), are rare systemic diseases causing necrotizing inflammation of small blood vessels. Renal involvement is common, leading to acute kidney injury with hematuria and proteinuria. Diagnosis is based on serological tests (PR3-ANCA, MPO-ANCA) and renal histology via biopsy, which helps assess the extent of lesions. Scores and classifications have been validated to predict the progression toward end-stage renal disease. Therapeutically, induction treatment (3 to 6 months) relies on corticosteroids combined with immunosuppressants such as cyclophosphamide or rituximab. Maintenance therapy (24 to 48 months) aims to prevent relapses, with rituximab proving superior to azathioprine. Avacopan, a C5a receptor inhibitor, offers a promising alternative by reducing dependence on corticosteroids in the induction phase. The KDIGO 2024 guidelines recommend early kidney biopsy and advise the use of these immunosuppressive treatments according to standardized protocols. These guidelines also integrate innovative therapeutic options like avacopan, providing new perspectives in the management of ANCA-associated vasculitis.","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"80 9","pages":"556-562"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0